Skip to content or view screen version

Hidden Article

This posting has been hidden because it breaches the Indymedia UK (IMC UK) Editorial Guidelines.

IMC UK is an interactive site offering inclusive participation. All postings to the open publishing newswire are the responsibility of the individual authors and not of IMC UK. Although IMC UK volunteers attempt to ensure accuracy of the newswire, they take no responsibility legal or otherwise for the contents of the open publishing site. Mention of external web sites or services is for information purposes only and constitutes neither an endorsement nor a recommendation.

Protalix gets FDA approval for Gaucher's trial: The company's molecule is a prop

Mr Roger K. Olsson | 15.07.2007 21:24 | Health | London

Giuen Media

Sunday, July 15, 2007

Jul. 15, 2007 (McClatchy-Tribune Regional News delivered by Newstex) --
Protalix Biotherapeutics Inc. (AMEX:PLX) has obtained US Food and Drug Administration (FDA) approval for the final design of its Phase III clinical trial for prGCD for the treatment of Gaucher disease, a lysosomal storage disorder in humans. The FDA approved the trial under its Special Protocol Assessment (SPA) process./ The company plans to start the trial during the third quarter of 2007.

prGCD is a proprietary plant cell expressed recombinant form of human gene Glucocerebrosidase (GCD). It is a biosimilar product to an existing drug, developed by Genzyme Corp. (Nasdaq:GENZ); Protalix was therefore able to leapfrog Phase II clinical trials.

The trial will be Protalix's large-scale effectiveness human trial of prGCD. The chances of success are much greater than usual for Phase III trials because of the molecule's similarity to Genzyme's molecule, whose effective has already been demonstrated.

Newstex ID: KRTB-0262-18145660

Delivered by Newstex LLC

Mr Roger K. Olsson
- e-mail:
- Homepage: